Abstract:Context Oridonin (ORI) has obvious anticancer effects, but its solubility is poor. Nanocrystal (NC) is a novel nano-drug delivery system for increasing bioavailability for ORI. However, the endocytosis and transcytosis behaviours of oridonin nanocrystals (ORI-NCs) through epithelial membrane are still unclear. Objectives ORI-NCs were prepared and characterized. The in vitro cytotoxicity and endocytosis and transcytosis process on Madin-Darby canine kidney (MDCK) monolayer were investigated. Materials and methods Anti-solvent precipitation method was adopted in preparation of ORI-NCs. Differential scanning calorimetry (DSC) and X-ray diffraction (XRD) were adopted to explore crystallography of ORI-NCs. Sulforhodamine B (SRB) method was used to test the inhibition effect on proliferation of MDCK cells. Quantitative analysis by HPLC was performed to study the endocytosis and transcytosis of ORI-NCs and ORI bulk drug, and the process was observed by confocal laser spectrum microscopy (CLSM) and flow cytometry. Results The particle size of ORI-NCs was about 274 nm. The crystallography form of ORI was not changed after prepared into NCs. The dissolution rate of ORI-NCs was higher than pure ORI in 120 min. At higher concentrations (34, 84 and 135 μg/mL), ORI-NCs significantly reduced the cell viability compared with free ORI (p < 0.05, p < 0.01). ORI-NCs demonstrated higher endocytosis in MDCK cells than free ORI (p < 0.01). In the transport process, ORI-NC was taken up into cells in an intact form, and excreted out from basolateral membrane of polarized epithelial cells in an intact form. The internalization and transmembrane amount increased as a function of time. Conclusions ORI-NCs transported through the MDCK monolayers in an intact form.

In vitro and in vivo evaluation of oridonin-loaded long circulating nanostructured lipid carriers

In Vivo Studies On The Oridonin-Loaded Nanostructured Lipid Carriers

Studies on the Oridonin-Loaded Poly(d,l-Lactic Acid) Nanoparticles in Vitro and in Vivo

Preparation And Characteristics Of Oridonin-Loaded Nanostructured Lipid Carriers As A Controlled-Release Delivery System

Preparation of oridonin-loaded solid lipid nanoparticles and studies on them in vitro and in vivo

Galactosylated bovine serum albumin nanoparticles for parenteral delivery of oridonin: tissue distribution and pharmacokinetic studies.

Preparation and Characterization of Oridonin-loaded Poly (caprolactone)-Poly (ethylene oxide)-Poly (caprolactone) Copolymer Nanoparticles

Synthesis, characterization, in vitro and in vivo evaluation of PEGylated oridonin conjugates.

Nanostructured lipid carriers used for oral delivery of oridonin: an effect of ligand modification on absorption.

Biodegradable self-assembled MPEG-PCL micelles for hydrophobic oridonin delivery in vitro.

Galactosylated Chitosan Nanoparticles for Hepatocyte-Targeted Delivery of Oridonin

In Vitro and in Vivo Studies of Galactose-Modified Liver-Targeting Liposomes.

Preparation and Characterization of Galactosylated Bovine Serum Albumin Nanoparticles for Liver-Targeted Delivery of Oridonin.

Preparation of Oridonin Nanocrystals and Study of Their Endocytosis and Transcytosis Behaviours on MDCK Polarized Epithelial Cells.

Oridonin-loaded poly(ε-caprolactone)–poly(ethylene oxide)–poly(ε-caprolactone) copolymer nanoparticles: Preparation, characterization, and antitumor activity on mice with transplanted hepatoma

Preparation and in Vitro Properties of Oridonin-Loaded Polylactic-acid Nanoparticles

Novel Galactosylated Biodegradable Nanoparticles for Hepatocyte-Delivery of Oridonin

Optimization and Evaluation of Oridonin-loaded Soluplus®-Pluronic P105 Mixed Micelles for Oral Administration

Preparation, Characterization and Pharmacokinetics of Amoitone B-loaded Long Circulating Nanostructured Lipid Carriers.

Oridonin Loaded Solid Lipid Nanoparticles Enhanced Antitumor Activity in MCF-7 Cells